Safety, Tolerability, and Pharmacodynamic Effect Study of PUR118

A Four-Part Study to Evaluate the Safety, Tolerability and Pharmacodynamic Effects of PUR118 and Placebo in Normal Healthy Volunteers and Subjects With COPD

The purpose of this study is to establish single and multiple dose safety in healthy subjects and subjects with mild chronic pulmonary obstructive disease (COPD). In addition, the study will evaluate preliminary proof of concept endpoints in COPD subjects such as biomarkers in sputum and mucociliary clearance.

Study Overview

• Status: Completed
• Conditions: Chronic Obstructive Pulmonary Disease
• Intervention / Treatment: Drug: PUR118

Detailed Description

The proposed initial trial in healthy subjects and subjects with mild COPD will establish the tolerability of PUR118 in these subjects over single and short multi-day dosing periods. The study will also provide preliminary data regarding PUR118's potential impact on biomarkers in COPD. Finally, this trial will assess PUR118's effect on mucociliary clearance. This is a four part study enrolling healthy volunteers in a single ascending dose design (SAD; Part I), followed by multiple ascending dose design (MAD; Part II). Contingent on demonstration of safety in a healthy subject population, the study will enroll mild COPD subjects for a short multi-dose design (Part III) incorporating safety and pharmacodynamic endpoints. Lastly Part IV of the trial will assess the effect of PUR118 on mucociliary clearance in mild COPD subjects.

• Study Type: Interventional
• Enrollment (Actual): 90
• Phase: Phase 1

Contacts and Locations

Study Locations

• United Kingdom
  • Nottingham, United Kingdom, NG11 6JS
    • Quotient Bioresearch

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 70 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Main Inclusion Criteria Parts I & II

• Healthy males or non pregnant, non lactating healthy females;
• Age 18-65 years of age;
• Must be willing and able to communicate in English and participate in the whole study;
• Must provide written informed consent.

Main Exclusion Criteria Parts I & II

• Current smokers and those who have smoked within the last 12 months;
• Females of child bearing age not willing to use an acceptable form of contraception;
• Presence or history of allergy requiring treatment;
• Serious adverse reaction or hypersensitivity to any drug;

Main Inclusion Criteria: Parts III and IV

• Males or non pregnant, non lactating females;
• Age 45-70 years;
• Current (Part III only) or ex-smokers who at least a 15 pack-year smoking history. For Part IV, subjects must be non-smokers for at least 3 months;
• Medically stable, with no evidence of uncontrolled co-existing conditions at screening;
• Must not be taking any inhaled or oral corticosteroids;
• FEV1/FVC ratio <70% and FEV1 60 - 80% (or >/= 60% for Part IV only) of predicted following administration of a bronchodilator;
• Patients must have a medical history of COPD confirmed by their General Practitioner (GP) or treating hospital physician or must have a chest x-ray (CXR) which is normal or consistent with mild COPD and excludes other clinically significant respiratory abnormalities;
• Must be willing and able to communicate in English and participate in the whole study;
• Must provide written informed consent.

Main Exclusion Criteria: Parts III and IV

• Must agree to use an adequate method of contraception;
• Upper respiratory tract infection within 30 days of the first study day, or lower respiratory tract infection within the last 60 days;
• Patients taking medication that may affect the respiratory tract within 14 days of the first study day other than their usual COPD medication;
• No active exacerbations requiring antibiotics or steroids within 60 days of dosing.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: PUR118	Drug: PUR118; inhaled

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
Safety and tolerability assessed by changes in clinical signs and symptoms, clinical safety laboratory tests, vital signs, ECG, spirometry, oxygen saturation, telemetry and adverse events	2 weeks

Secondary Outcome Measures

Outcome Measure	Time Frame
Assessment of biomarkers of inflammation and COPD in induced sputum in mild COPD subjects after short multi-dosing with PUR118 compared to baseline	2 days
Assessment of changes in mucociliary clearance after treatment with PUR118 in mild COPD subjects compared to baseline	single dose

Collaborators and Investigators

• Sponsor: Pulmatrix Inc.
• Collaborators: Quotient Bioresearch
• Investigators: Principal Investigator: Stuart Mair, MD, Quotient Bioresearch

Study record dates

Study Major Dates

• Study Start: February 1, 2011
• Primary Completion (Actual): June 1, 2012
• Study Completion (Actual): June 1, 2012

Study Registration Dates

• First Submitted: April 7, 2011
• First Submitted That Met QC Criteria: April 11, 2011
• First Posted (Estimate): April 12, 2011

Study Record Updates

• Last Update Posted (Estimate): September 7, 2012
• Last Update Submitted That Met QC Criteria: September 6, 2012
• Last Verified: September 1, 2012

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Respiratory Tract Diseases; Lung Diseases; Lung Diseases, Obstructive; Pulmonary Disease, Chronic Obstructive
• Other Study ID Numbers: 601-0004